{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:24Z","timestamp":1791919644084,"version":"4.3.4"},"reference-count":43,"publisher":"Bentham Science Publishers Ltd.","issue":"40","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:sec>\n<jats:title>:<\/jats:title>\n<jats:p>SARS-CoV-2 invades the respiratory tract epithelium and can result in systemic\ninflammation prior to an infection caused by either bacteria or fungus. COVID-19-\nassociated mucormycosis (CAM) is a serious condition that can occur during the time of\nthe disease due to increased administration of corticosteroids. Various studies have\nsuggested that statins may improve clinical outcomes in COVID-19 patients. According\nto several preclinical reports, fluvastatin was shown to exert direct and indirect synergistic\nantifungal activity. Thus, fluvastatin could be considered a potential antifungal agent\nwhen no other option is available. Furthermore, in comparison with other statins, fluvastatin\nexhibits the fewest drug\/drug interactions with anti-Mucorales azoles (e.g., isavuconazole\nand posaconazole), as well as with medicines that are used in solid organ transplant\nrecipients (e.g., cyclosporine) and HIV-positive individuals (e.g., ritonavir); two groups\nof patients that have a higher risk of infection with Mucorales fungi following a SARSCoV-\n2 infection.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867331666230706152616","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T06:08:31Z","timestamp":1688710111000},"page":"6649-6655","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fluvastatin: A Choice for COVID-19-associated Mucormycosis Management"],"prefix":"10.2174","volume":"31","author":[{"given":"Alireza","family":"Tavakkoli","sequence":"first","affiliation":[{"name":"Department of Pharmacognosy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Johnston","sequence":"additional","affiliation":[{"name":"Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-\nKansas City, Kansas City, MO 64110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[{"name":"Applied Biomedical Research Center, Mashhad University\nof Medical Sciences, Mashhad, Iran"},{"name":"Biotechnology Research Center, Pharmaceutical Technology Institute,\nMashhad University of Medical Sciences, Mashhad, Iran"},{"name":"School of Medicine, The University of Western\nAustralia, Perth, Australia"},{"name":"School of Pharmacy, Mashhad University of Medical Sciences, Mashhad,\nIran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"102557","DOI":"10.1016\/j.tmaid.2023.102557","volume":"52","author":"Dam P.","year":"2023","unstructured":"Dam P.; Cardoso M.H.; Mandal S.; Franco O.L.; Sa\u011f\u0131ro\u011flu P.; Polat O.A.; Kokoglu K.; Mondal R.; Mandal A.K.; Ocsoy I.; Surge of mucormycosis during the COVID-19 pandemic. Travel Med Infect Dis  2023,52,102557","journal-title":"Travel Med Infect Dis"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S1473-3099(10)70316-9","volume":"11","author":"Sun H.Y.","year":"2011","unstructured":"Sun H.Y.; Singh N.; Mucormycosis: Its contemporary face and management strategies. Lancet Infect Dis  2011,11(4),301-311","journal-title":"Lancet Infect Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"794176","DOI":"10.3389\/fmicb.2021.794176","volume":"12","author":"Dogra S.","year":"2022","unstructured":"Dogra S.; Arora A.; Aggarwal A.; Passi G.; Sharma A.; Singh G.; Barnwal R.P.; mucormycosis amid COVID-19 crisis: Pathogenesis, diagnosis, and novel treatment strategies to combat the spread. Front Microbiol  2022,12,794176","journal-title":"Front Microbiol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"102146","DOI":"10.1016\/j.dsx.2021.05.019","volume":"15","author":"Singh A.K.","year":"2021","unstructured":"Singh A.K.; Singh R.; Joshi S.R.; Misra A.; Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr  2021,15(4),102146","journal-title":"Diabetes Metab Syndr"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/myc.13338","volume":"64","author":"Pal R","year":"2021","unstructured":"Pal R; Singh B; Bhadada SK; Banerjee M; Bhogal RS; Hage N; Kumar A; COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses  2021,64(12),1452-1459","journal-title":"Mycoses"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"e0009921","DOI":"10.1371\/journal.pntd.0009921","volume":"15","author":"Aranjani J.M.","year":"2021","unstructured":"Aranjani J.M.; Manuel A.; Abdul Razack H.I.; Mathew S.T.; COVID-19 associated mucormycosis: Evidence-based critical review of an emerging infection burden during the pandemic\u2019s second wave in India. PLoS Negl Trop Dis  2021,15(11),e0009921","journal-title":"PLoS Negl Trop Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"154375","DOI":"10.1016\/j.metabol.2020.154375","volume":"113","author":"Ganjali S.","year":"2020","unstructured":"Ganjali S.; Bianconi V.; Penson P.E.; Pirro M.; Banach M.; Watts G.F.; Sahebkar A.; Commentary: Statins, COVID-19, and coronary artery disease: Killing two birds with one stone. Metabolism  2020,113,154375","journal-title":"Metabolism"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"101024","DOI":"10.1016\/j.arr.2020.101024","volume":"58","author":"Bahrami A.","year":"2020","unstructured":"Bahrami A.; Bo S.; Jamialahmadi T.; Sahebkar A.; Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev  2020,58,101024","journal-title":"Ageing Res Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.phrs.2018.08.014","volume":"135","author":"Bahrami A.","year":"2018","unstructured":"Bahrami A.; Parsamanesh N.; Atkin S.L.; Banach M.; Sahebkar A.; Effect of statins on toll-like receptors: A new insight to pleiotropic effects. Pharmacol Res  2018,135,230-238","journal-title":"Pharmacol Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"105986","DOI":"10.1016\/j.phrs.2021.105986","volume":"175","author":"Bland A.R.","year":"2022","unstructured":"Bland A.R.; Payne F.M.; Ashton J.C.; Jamialahmadi T.; Sahebkar A.; The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res  2022,175,105986","journal-title":"Pharmacol Res"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.5114\/aoms\/141155","volume":"17","author":"Khalifeh M.","year":"2021","unstructured":"Khalifeh M.; Penson P.; Banach M.; Sahebkar A.; Statins as anti-pyroptotic agents. Arch Med Sci  2021,17(5),1414-1417","journal-title":"Arch Med Sci"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12016-020-08791-9","volume":"60","author":"Koushki K.","year":"2021","unstructured":"Koushki K.; Shahbaz S.K.; Mashayekhi K.; Sadeghi M.; Zayeri Z.D.; Taba M.Y.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clin Rev Allergy Immunol  2021,60(2),175-199","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.5114\/aoms.2019.89330","volume":"17","author":"Sohrevardi S.","year":"2019","unstructured":"Sohrevardi S.; Nasab F.; Mirjalili M.; Bagherniya M.; Tafti A.; Jarrahzadeh M.; Azarpazhooh M.; Saeidmanesh M.; Banach M.; Jamialahmadi T.; Sahebkar A.; Effect of atorvastatin on delirium status of patients in the intensive care unit: A randomized controlled trial. Arch Med Sci  2019,17(5),1423-1428","journal-title":"Arch Med Sci"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1136\/postgradmedj-2020-139172","volume":"98","author":"Pal R","year":"2021","unstructured":"Pal R; Banerjee M; Yadav U; Bhattacharjee S; Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad Med J  2021,98(1159),354-359","journal-title":"Postgrad Med J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.atherosclerosis.2021.06.911","volume":"330","author":"Kollias A.","year":"2021","unstructured":"Kollias A.; Kyriakoulis K.G.; Kyriakoulis I.G.; Nitsotolis T.; Poulakou G.; Stergiou G.S.; Syrigos K.; Statin use and mortality in COVID-19 patients: Updated systematic review and meta-analysis. Atherosclerosis  2021,330,114-121","journal-title":"Atherosclerosis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"ofab284","DOI":"10.1093\/ofid\/ofab284","volume":"8","author":"Yetmar Z.A.","year":"2021","unstructured":"Yetmar Z.A.; Chesdachai S.; Kashour T.; Riaz M.; Gerberi D.J.; Badley A.D.; Berbari E.F.; Tleyjeh I.M.; Prior statin use and risk of mortality and severe disease from coronavirus disease 2019: A systematic review and meta-analysis. Open Forum Infect Dis  2021,8(7),ofab284","journal-title":"Open Forum Infect Dis"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.amjcard.2020.08.004","volume":"134","author":"Kow C.S.","year":"2020","unstructured":"Kow C.S.; Hasan S.S.; Meta-analysis of effect of statins in patients with COVID-19. Am J Cardiol  2020,134,153-155","journal-title":"Am J Cardiol"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40256-021-00490-w","volume":"22","author":"Kow C.S.","year":"2022","unstructured":"Kow C.S.; Hasan S.S.; The association between the use of statins and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis. Am J Cardiovasc Drugs  2022,22(2),167-181","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ijid.2021.08.004","volume":"110","author":"Diaz-Arocutipa C.","year":"2021","unstructured":"Diaz-Arocutipa C.; Melgar-Talavera B.; Alvarado-Yarasca \u00c1.; Saravia-Bartra M.M.; Cazorla P.; Belzusarri I.; Hernandez A.V.; Statins reduce mortality in patients with COVID-19: An updated meta-analysis of 147 824 patients. Int J Infect Dis  2021,110,374-381","journal-title":"Int J Infect Dis"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.5114\/aoms\/132950","volume":"17","author":"Vahedian-Azimi A.","year":"2021","unstructured":"Vahedian-Azimi A.; Mohammadi S.; Beni F.; Banach M.; Guest P.; Jamialahmadi T.; Sahebkar A.; Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch Med Sci  2021,17(3),579-595","journal-title":"Arch Med Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1080\/07853890.2021.1933165","volume":"53","author":"Wu K.S.","year":"2021","unstructured":"Wu K.S.; Lin P.C.; Chen Y.S.; Pan T.C.; Tang P.L.; The use of statins was associated with reduced COVID-19 mortality: A systematic review and meta-analysis. Ann Med  2021,53(1),874-884","journal-title":"Ann Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"e0253576","DOI":"10.1371\/journal.pone.0253576","volume":"16","author":"Chow R.","year":"2021","unstructured":"Chow R.; Im J.; Chiu N.; Chiu L.; Aggarwal R.; Lee J.; Choi Y.G.; Prsic E.H.; Shin H.J.; The protective association between statins use and adverse outcomes among COVID-19 patients: A systematic review and meta-analysis. PLoS One  2021,16(6),e0253576","journal-title":"PLoS One"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1136\/postgradmedj-2021-140409","volume":"98","author":"Zein A.","year":"2021","unstructured":"Zein A.; Sulistiyana C.S.; Khasanah U.; Wibowo A.; Lim M.A.; Pranata R.; Statin and mortality in COVID-19: A systematic review and meta-analysis of pooled adjusted effect estimates from propensity-matched cohorts. Postgrad Med J  2021,98(1161),503-508","journal-title":"Postgrad Med J"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1517\/14656566.3.11.1631","volume":"3","author":"Lawrence J.M.","year":"2002","unstructured":"Lawrence J.M.; Reckless J.P.D.; Fluvastatin. Expert Opin Pharmacother  2002,3(11),1631-1641","journal-title":"Expert Opin Pharmacother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"107483","DOI":"10.1016\/j.pharmthera.2020.107483","volume":"208","author":"Tavakkoli A.","year":"2020","unstructured":"Tavakkoli A.; Johnston T.P.; Sahebkar A.; Antifungal effects of statins. Pharmacol Ther  2020,208,107483","journal-title":"Pharmacol Ther"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1556\/ABiol.61.2010.3.11","volume":"61","author":"Galg\u00f3czy L.","year":"2010","unstructured":"Galg\u00f3czy L.; Luk\u00e1cs G.; Nyilasi I.; Papp T.; V\u00e1gv\u00f6lgyi C.; Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes. Acta Biol Hung  2010,61(3),356-365","journal-title":"Acta Biol Hung"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1439-0507.2008.01634.x","volume":"52","author":"Galg\u00f3czy L.","year":"2009","unstructured":"Galg\u00f3czy L.; Papp T.; V\u00e1gv\u00f6lgyi C.; In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses  2009,52(5),447-453","journal-title":"Mycoses"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.fgb.2019.04.008","volume":"129","author":"Nagy G.","year":"2019","unstructured":"Nagy G.; Vaz A.G.; Szebenyi C.; Tak\u00f3 M.; T\u00f3th E.J.; Csernetics \u00c1.; Bencsik O.; Szekeres A.; Homa M.; Ayaydin F.; Galg\u00f3czy L.; V\u00e1gv\u00f6lgyi C.; Papp T.; CRISPR-Cas9-mediated disruption of the HMG-CoA reductase genes of Mucor circinelloides and subcellular localization of the encoded enzymes. Fungal Genet Biol  2019,129,30-39","journal-title":"Fungal Genet Biol"},{"key":"ref=29","first-page":"33","volume":"54","author":"Nyilasi I.","year":"2010","unstructured":"Nyilasi I.; Kocsub\u00e9 S.; Galg\u00f3czy L.; Papp T.; Pesti M.; V\u00e1gv\u00f6lgyi C.; Effect of different statins on the antifungal activity of polyene antimycotics. Acta Biol Szeged  2010,54(1),33-36","journal-title":"Acta Biol Szeged"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1099\/jmm.0.013946-0","volume":"59","author":"Nyilasi I.","year":"2010","unstructured":"Nyilasi I.; Kocsub\u00e9 S.; Pesti M.; Luk\u00e1cs G.; Papp T.; V\u00e1gv\u00f6lgyi C.; In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol  2010,59(2),200-205","journal-title":"J Med Microbiol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s10482-008-9287-2","volume":"95","author":"Luk\u00e1cs G.","year":"2009","unstructured":"Luk\u00e1cs G.; Papp T.; Somogyv\u00e1ri F.; Csernetics \u00c1.; Nyilasi I.; V\u00e1gv\u00f6lgyi C.; Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides. Antonie van Leeuwenhoek  2009,95(1),55-64","journal-title":"Antonie van Leeuwenhoek"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1471-2180-14-93","volume":"14","author":"Nagy G.","year":"2014","unstructured":"Nagy G.; Farkas A.; Csernetics \u00c1.; Bencsik O.; Szekeres A.; Nyilasi I.; V\u00e1gv\u00f6lgyi C.; Papp T.; Transcription of the three HMG-CoA reductase genes of Mucor circinelloides. BMC Microbiol  2014,14(1),93","journal-title":"BMC Microbiol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.2174\/1566524019666190520094644","volume":"19","author":"Rana R.","year":"2019","unstructured":"Rana R.; Sharma R.; Kumar A.; Repurposing of fluvastatin against candida albicans CYP450 lanosterol 14 alpha-demethylase, a target enzyme for antifungal therapy: An in silico and in vitro study. Curr Mol Med  2019,19(7),506-524","journal-title":"Curr Mol Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41577-018-0094-3","volume":"19","author":"Parihar S.P.","year":"2019","unstructured":"Parihar S.P.; Guler R.; Brombacher F.; Statins: A viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol  2019,19(2),104-117","journal-title":"Nat Rev Immunol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"e22655","DOI":"10.1371\/journal.pone.0022655","volume":"6","author":"Jouneau S.","year":"2011","unstructured":"Jouneau S.; Bonizec M.; Belleguic C.; Desrues B.; Brinchault G.; Galaine J.; Gangneux J.P.; Martin-Chouly C.; Anti-inflammatory effect of fluvastatin on IL-8 production induced by Pseudomonas aeruginosa and Aspergillus fumigatus antigens in cystic fibrosis. PLoS One  2011,6(8),e22655","journal-title":"PLoS One"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","volume":"19","author":"Cornely O.A.","year":"2019","unstructured":"Cornely O.A.; Alastruey-Izquierdo A.; Arenz D.; Chen S.C.A.; Dannaoui E.; Hochhegger B.; Hoenigl M.; Jensen H.E.; Lagrou K.; Lewis R.E.; Mellinghoff S.C.; Mer M.; Pana Z.D.; Seidel D.; Sheppard D.C.; Wahba R.; Akova M.; Alanio A.; Al-Hatmi A.M.S.; Arikan-Akdagli S.; Badali H.; Ben-Ami R.; Bonifaz A.; Bretagne S.; Castagnola E.; Chayakulkeeree M.; Colombo A.L.; Corzo-Le\u00f3n D.E.; Drgona L.; Groll A.H.; Guinea J.; Heussel C.P.; Ibrahim A.S.; Kanj S.S.; Klimko N.; Lackner M.; Lamoth F.; Lanternier F.; Lass-Floerl C.; Lee D.G.; Lehrnbecher T.; Lmimouni B.E.; Mares M.; Maschmeyer G.; Meis J.F.; Meletiadis J.; Morrissey C.O.; Nucci M.; Oladele R.; Pagano L.; Pasqualotto A.; Patel A.; Racil Z.; Richardson M.; Roilides E.; Ruhnke M.; Seyedmousavi S.; Sidharthan N.; Singh N.; Sinko J.; Skiada A.; Slavin M.; Soman R.; Spellberg B.; Steinbach W.; Tan B.H.; Ullmann A.J.; Vehreschild J.J.; Vehreschild M.J.G.T.; Walsh T.J.; White P.L.; Wiederhold N.P.; Zaoutis T.; Chakrabarti A.; Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in Cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis  2019,19(12),e405-e421","journal-title":"Lancet Infect Dis"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s40265-020-01306-y","volume":"80","author":"Chen L.","year":"2020","unstructured":"Chen L.; Krekels E.H.J.; Verweij P.E.; Buil J.B.; Knibbe C.A.J.; Br\u00fcggemann R.J.M.; Pharmacokinetics and pharmacodynamics of posaconazole. Drugs  2020,80(7),671-695","journal-title":"Drugs"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mycmed.2018.02.002","volume":"28","author":"Ledoux M.P.","year":"2018","unstructured":"Ledoux M.P.; Denis J.; Nivoix Y.; Herbrecht R.; Isavuconazole: A new broad-spectrum azole. Part 2: Pharmacokinetics and clinical activity. J Mycol Med  2018,28(1),15-22","journal-title":"J Mycol Med"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/myc.12419","volume":"58","author":"Dioverti M.V.","year":"2015","unstructured":"Dioverti M.V.; Cawcutt K.A.; Abidi M.; Sohail M.R.; Walker R.C.; Osmon D.R.; Gastrointestinal mucormycosis in immunocompromised hosts. Mycoses  2015,58(12),714-718","journal-title":"Mycoses"},{"key":"ref=40","first-page":"639","volume":"64","author":"de P\u00e1dua Borges R.","year":"2020","unstructured":"de P\u00e1dua Borges R.; Degobi N.A.H.; Bertoluci M.C.; Choosing statins: A review to guide clinical practice. Arch Endocrinol Metab  2020,64(6),639-653","journal-title":"Arch Endocrinol Metab"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40256-017-0222-7","volume":"17","author":"Wiggins B.S.","year":"2017","unstructured":"Wiggins B.S.; Lamprecht D.G.; Page R.L.; Saseen J.J.; Recommendations for managing drug\u2013drug interactions with statins and HIV medications. Am J Cardiovasc Drugs  2017,17(5),375-389","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s15010-004-3136-7","volume":"32","author":"Benesic A.","year":"2004","unstructured":"Benesic A.; Zilly M.; Kluge F.; Weissbrich B.; Winzer R.; Klinker H.; Langmann P.; Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: Comparison of efficacy and interaction with indinavir. Infection  2004,32(4),229-233","journal-title":"Infection"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1093\/jac\/dkq002","volume":"65","author":"Milazzo L.","year":"2010","unstructured":"Milazzo L.; Caramma I.; Mazzali C.; Cesari M.; Olivetti M.; Galli M.; Antinori S.; Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV\/hepatitis C virus genotype 1 co-infected patients: An open-label randomized controlled study. J Antimicrob Chemother  2010,65(4),735-740","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230706152616","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218476\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867331666230706152616","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T09:39:24Z","timestamp":1733737164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218476\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":43,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867331666230706152616","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}